PFAS



| Properties | Per- and polyfluoroalkyl substances (PFAS) are a family of thousands of synthetic chemicals; relatively few have been studied for their effect on health Used widely to reduce friction or resist oil, water, and stains Widespread and persistent in the environment Among studied PFAS: absorbed in intestines and lungs; bind to serum and tissue proteins; most not metabolized; half-lives range from a few days to 8+ years | | |
|---|--|--|--|
| Human Exposure | Nearly all people in the U.S. have had exposure to PFAS PFOS, PFOA, and PFHxS exposure is decreasing in the U.S. population, in part because of production phase-outs Population exposures to substitute PFAS (e.g., GenX) are not well studied Communities with PFAS contamination of water or food are often near facilities that have manufactured, used, or handled PFAS Ingestion of PFAS in water and food is a main route of exposure; ingestion of dust and residue from PFAS-containing products can also result in exposure Inhalation is not a typical route of exposure for the general population but can occur with PFAS-containing dust, aerosols, or fumes Children can be exposed by drinking formula mixed with PFAS-containing water, drinking breastmilk from persons exposed to PFAS, ingesting dust or dirt, and through hand to mouth behaviors with textiles treated with stain protectants Some PFAS cross the placenta and enter umbilical cord blood | | |
| Health Effects | Research is ongoing to understand the mechanisms of PFAS toxicity The epidemiological evidence suggests associations between increases in exposure to (specific) PFAS and certain health effects Increases in cholesterol levels (PFOA, PFOS, PFNA, PFDA) Small decreases in birth weight (PFOA, PFOS) Lower antibody response to some vaccines (PFOA, PFOS, PFHxS, PFDA) Kidney and testicular cancer (PFOA) Pregnancy-induced hypertension or preeclampsia (PFOA, PFOS) Changes in liver enzymes (PFOA, PFOS, PFHxS) The risk of health effects associated with PFAS depends on Exposure factors (e.g., dose, frequency, route, and duration) Individual factors (e.g., sensitivity and chronic disease burden) Other determinants of health (e.g., access to safer water and quality healthcare) | | |
| Clinical Evaluation and Management | Main goals are to Identify and reduce PFAS exposures Promote standard age-appropriate preventive care measures for physical health, mental health, and wellness Clinical presentation: PFAS toxicity is not associated with characteristic signs or symptoms Taking an exposure history can help identify PFAS exposures and determine actions to reduce exposures; ask about possible current and past PFAS exposure sources, durations, frequency, and magnitude | | |

| Clinical Evaluation and Management (continued) | Exposure reduction strategies for Installing water filtration system Limiting or avoiding consume Choosing products without I Breastfeeding is optimal due to indecision to breastfeed based on Clinicians can counsel patients of the benefits and limitations of PF Results (current levels of PF, exposures in the case of PF, PFAS blood test results do results do not indicate where predict future health problem Comparing PFAS results acr Potential relief from psycholic Having information that coul Potential for false positives for introgenic complications from | llow from the em or using ption of compression of compression of compression of the extension of the extensi | he exposure history; examples include ag an alternative water source ontaminated fish, meat, eggs, or dairy n possible enefits; clinicians can assist patients in their ecific to the patient and child to pursue blood testing with an understanding of clood) could reflect recent exposures or past ag half-lives sources of exposure ent illness can be attributed to PFAS exposure or tories can be difficult ress if PFAS levels are normal sposure reduction decisions ning based on PFAS blood test results and al evaluation and treatment reening blood levels for PFAS ble to remove PFAS from the body |
|--|---|--|---|
| Additional Expertise | Other professionals can help with evaluation and monitoring/treatm Board-certified clinicians sp medical toxicology, and ped Occupational health clinician State or local health/environ | n exposure nent plans: ecializing i iatric envir ns mental dej | e histories and reduction methods, and patient n occupational and environmental medicine, onmental health partments |
| More Resources | ATSDR PFAS Information for Clinicians (full document) American College of Medical Toxicology Association of Occupational and Environmental Clinics ATSDR Toxicological Profile for PFAS ATSDR PFAS and Your Health ATSDR PFAS Blood Level Estimation Tool ATSDR Minimal Risk Levels for PFAS CDC's Breastfeeding: Why it Matters CDC National Report on Human Exposure to Environmental Chemicals EPA's Meaningful and Achievable Steps You Can Take to Reduce Your Risk NASEM Guidance on PFAS Testing and Health Outcomes National Institute for Occupational Safety and Health PFAS webpage Pediatric Environmental Health Specialty Units | | |
| Acronyms: PFAS: Per- and pol PFDA: Perfluoroded | yfluoroalkyl substances canoic acid | PFNA: PFOA: | Perfluorononanoic acid Perfluorooctanoic acid |

PFHxS: Perfluorohexane sulfonic acid

PFOS: Perfluorooctane sulfonic acid

